Physician profile
Michael Duffey
NPI 1417134248
$2,674.15
in general payments reported to CMS, 2019-2025
22 companies · $535 in 2025
The $535 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $147 · 2021: $234 · 2022: $493 · 2023: $622 · 2024: $357 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.60 |
| Education | $122.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,010.67 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $810.81 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $107.37 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $106.91 | 2022-2024 | Sotyktu |
| Ucb, INC. | $69.15 | 2023-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $64.34 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $60.55 | 2021-2024 | |
| Amgen INC. | $55.53 | 2022-2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $50.96 | 2022-2023 | Dupixent |
| Pfizer INC. | $47.70 | 2022-2023 | |
| Incyte Corporation | $37.52 | 2022-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $32.29 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $29.54 | 2023-2024 | Vtama |
| Genzyme Corporation | $28.35 | 2019-2020 | |
| Organon LLC | $26.28 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $25.03 | 2023 | Vyjuvek |
| Genentech USA, INC. | $24.40 | 2019 | |
| Galderma Laboratories, L.P. | $23.77 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.87 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.06 | 2021 | |
| Leo Pharma INC. | $12.93 | 2019 | |
| Vyne Pharmaceuticals INC. | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Duffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.